MedTrace Logo

Sphingosine-1 Phosphate -Receptor Targeting and Microglial Activation

NCT02139696 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2018-05-11

No results posted yet for this study

Summary

To evaluate the usability of positron emission tomography imaging as a novel outcome measure in multiple sclerosis studies

Conditions

Interventions

RADIATION

PET and MRI

Patients will be imaged using PET and MRI at baseline, and twice during treatment

Sponsors & Collaborators

  • Turku University Hospital

    lead OTHER_GOV

Principal Investigators

  • Laura Airas, MD, PhD · Turku University Hospital

Eligibility

Min Age
18 Years
Max Age
58 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2015-01-31
Completion
2016-10-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02139696 on ClinicalTrials.gov